Papillary thyroid carcinoma (PTC) arises from the thyroid follicular epithelium and represents the most frequent thyroid malignancy. PTC is associated with gene rearrangements generating RET/PTC and TRK oncogenes, and to the BRAFV600E activating point mutation. A role of tumor-suppressor genes in the pathogenesis of PTC has not been assessed yet. The tissue inhibitor of metalloproteinase-3 (TIMP3) gene, encoding a metalloproteinases inhibitor and capable of inhibiting growth, angiogenesis, invasion and metastasis of several cancers, was found to be silenced by promoter methylation in a consistent fraction of PTCs, in association with tumor aggressiveness and BRAFV600E mutation, thus suggesting an oncosuppressor role. To explore this possibility, in this study we performed gene expression and functional studies. Analysis of gene expression data produced in our laboratory as well as meta-analysis of publicly available data sets confirmed the downregulation of TIMP3 gene expression in PTC with respect to normal thyroid. The functional consequences of TIMP3 downregulation were investigated in the PTC-derived NIM1 cell line, in which the expression of TIMP3 is silenced. Restoration of TIMP3 expression by exposure to soluble TIMP3 protein or by complementary DNA transfection had no effect on the growth rate of NIM1 cells. Instead, it affected the adhesive, migratory and invasive capabilities of NIM1 cells by modulating several proteins involved in these processes. A striking effect was observed in vivo, as TIMP3 reduced the tumorigenicity of NIM1 cells by repressing angiogenesis and macrophage infiltration. Our data indicate that the loss of TIMP3 expression exerts a functional role in the pathogenesis of PTC.
Papillary thyroid carcinoma (PTC) arises from the thyroid follicular epithelium and represents the most frequent thyroid malignancy. PTC is associated with gene rearrangements generating RET/PTC and TRK oncogenes, and to the BRAFV600E activating point mutation. A role of tumor-suppressor genes in the pathogenesis of PTC has not been assessed yet. The tissue inhibitor of metalloproteinase-3 (TIMP3) gene, encoding a metalloproteinases inhibitor and capable of inhibiting growth, angiogenesis, invasion and metastasis of several cancers, was found to be silenced by promoter methylation in a consistent fraction of PTCs, in association with tumor aggressiveness and BRAFV600E mutation, thus suggesting an oncosuppressor role. To explore this possibility, in this study we performed gene expression and functional studies. Analysis of gene expression data produced in our laboratory as well as meta-analysis of publicly available data sets confirmed the downregulation of TIMP3 gene expression in PTC with respect to normal thyroid. The functional consequences of TIMP3 downregulation were investigated in the PTC-derived NIM1 cell line, in which the expression of TIMP3 is silenced. Restoration of TIMP3 expression by exposure to soluble TIMP3 protein or by complementary DNA transfection had no effect on the growth rate of NIM1 cells. Instead, it affected the adhesive, migratory and invasive capabilities of NIM1 cells by modulating several proteins involved in these processes. A striking effect was observed in vivo, as TIMP3 reduced the tumorigenicity of NIM1 cells by repressing angiogenesis and macrophage infiltration. Our data indicate that the loss of TIMP3
Introduction
Thyroid cancer represents the most common endocrine malignancy, and its incidence has increased significantly over the past few decades. Papillary thyroid carcinoma (PTC), the most frequent neoplasia originating from the thyroid epithelium, accounts for B80% of all thyroid cancers (Hedinger et al., 1988) . PTC is characterized by rearrangements of RET (rearranged during transfection) and NTRK1 (neurotrophic tyrosine kinase, receptor, type 1) receptor tyrosine kinases, or by activating point mutations in the BRAF (v-raf murine sarcoma viral oncogene homolog B1) serine/threonine kinase. Activating point mutations in the RAS oncogenes are limited to the follicular variant of PTC (Greco et al., 2009) . Although the identification of PTC-associated oncogenes has provided a great contribution to the understanding of PTC pathogenesis, the molecular mechanisms underlying the development of these neoplasias are still far from being completely elucidated. At variance with other solid tumors, a role of tumorsuppressor genes in the molecular pathogenesis of thyroid tumors has not been assessed yet. Putative oncosuppressor genes relevant for thyroid carcinomas have been suggested by methylation studies (Xing 2007 (Xing , 2008 . In the past few years, some genes identified as downregulated in the context of gene expression studies were classified as tumor suppressors by functional studies, as their re-expression modulated transformed properties of thyroid carcinoma cell lines (Ferrario et al., 2008; Latini et al., 2008; Pallante et al., 2008; Vizioli et al., 2010; Zuo et al., 2010) .
Tissue inhibitor of metalloproteinase-3 (TIMP3) gene encodes a member of TIMP family molecules that inhibit the proteolytic activity of matrix metalloproteinases, a family of endopeptidases, involved in the degradation of extracellular matrix, whose activity is often increased in tumors. TIMP3 is a secreted protein and, unlike other TIMP family members, binds tightly to the extracellular matrix. In addition, TIMP-3 exhibits direct inhibitory activity against several ADAMs including tumor necrosis factor-a (TNF-a) convertase (TACE (tumor necrosis factor-a-converting enzyme) and ADAM-17 (ADAM metallopeptidase domain 17)) (Fata et al., 2001) , and this inhibition is crucial for controlling TNF-mediated inflammation (Mohammed et al., 2004) . TIMP-3 also inhibits cell shedding of several molecules (L-selectin, syndecans 1 and 4, interleukin-6 (IL-6) receptor and c-MET) and cleavage of insulin-like growth factor-binding proteins 3 and 5 (Fata et al., 2001) . TIMP3 has been proposed as a tumor suppressor in several human cancer types. Silencing of TIMP3 through promoter hypermethylation has been associated with poor prognosis in a range of human cancers including kidney, brain, colon (Bachman et al., 1999) , non-small cell lung (Zochbauer-Muller et al., 2001) and meningiomas (Barski et al., 2010) . Loss of TIMP3 expression, through loss of heterozigosity on chromosome 22q, is frequently observed in various cancers, such as secondary glioblastoma (Nakamura et al., 2005) and clear renal cell carcinomas (Masson et al., 2010) . Evidence is emerging that downregulation of TIMP3 expression in tumors can be achieved also through deregulation of microRNAs, as TIMP3 is a target of several microRNAs upregulated in human tumors such as miR21, miR181b, miR221 and 222 (Gabriely et al., 2008; Garofalo et al., 2009; Wang et al., 2010) . The tumor-suppressor role of TIMP3 is also documented by a large body of data showing its capability to inhibit growth, invasion and metastasis of several cancers (Anand-Apte et al., 1996; Qi et al., 2003) . Treatment of human melanoma, lung, prostate and breast cancer cells and xenografts with recombinant TIMP3 protein reduced cell proliferation, induced caspase-mediated apoptosis, sensitized cells to paclitaxel, and reduced tumor growth and metastasis (Mahller et al., 2008) . In melanoma cells, TIMP3 is involved in the stabilization of death receptors TNF receptor-1, FAS and TNF-related apoptosis-inducing ligand receptor-1 on the surface of cells, sensitizing them to apoptosis induced by their ligands (Ahonen et al., 2003) . Antitumoral effects of TIMP3 are also ascribed to its antiangiogenic properties, based on the ability to block the binding of vascular endothelial growth factor (VEGF) to its receptor (Qi et al., 2003) . Reduction of neovascularization was observed in tumor xenografts induced by melanoma, neuroblastoma and malignant peripheral nerve sheath tumor cells in which TIMP3 expression was restored by different approaches (Ahonen et al., 2003; Mahller et al., 2008) .
To investigate the role of TIMP3 in the pathogenesis of PTC, we used an integrated approach including analysis of several gene expression data sets and functional studies. TIMP3 was found to be downregulated in a consistent fraction of PTCs, with respect to normal thyroid. The functional consequences of TIMP3 downregulation were investigated in the PTCderived NIM1 cell line, in which the expression of TIMP3 is silenced by promoter hypermethylation.
Restoration of TIMP3 by treatment with soluble protein or by complementary DNA (cDNA) transfection had no effect on growth rate; however, it reduced migration, invasion and anchorage-independent growth of NIM1 cell line. in vivo tumorigenicity of NIM1 cells was reduced by TIMP3 restoration, and this was related to reduction of angiogenesis and macrophage infiltration.
Results
Expression analysis of TIMP3 in PTC samples and thyroid tumor cell lines Hypermethylation of TIMP3 promoter has been detected in a high proportion (53%) of PTCs and is associated with aggressiveness and BRAF mutation (Hu et al., 2006) . Based on the evidence that TIMP3 can also be regulated at post-transcriptional level by microRNAs, we thought that gene expression analysis could represent the most accurate method for the assessment of TIMP3 downregulation in PTC. To this end, we analyzed several microarray data of tumor and normal thyroid tissues. In cDNA microarray data produced in our laboratory (Ferrario et al., 2008) , in comparison with TIMP3 gene expression level of normal thyroid, TIMP3 downregulation was evident in both the classical histotype and the tall cell variant (Po0.01; Figure 1a ). Frequent downregulation of TIMP3 in comparison with normal samples was also observed when a number of independent data sets of microarray gene expression data of PTC samples, publicly available and all obtained using Affymetrix HG-U133 series platforms, were considered. As shown in Figure 1b , in the Giordano et al. (2005) data set, a significantly reduced expression of TIMP3 (Po0.05) was observed in the tall cell series (10 out of 26), although not in the classical histotype of PTC when compared with normal thyroid. In the data sets of both He et al. (2005) and Jarzab et al. (2005) , a statistically significant reduced (Po0.01) TIMP3 expression was displayed by PTC when compared with unaffected thyroid tissues from the same patients (Figures 1c and d) . Although not statistically significant, in the data set of Vasko et al. (2007) , both microscopically dissected central and invasive regions of PTC of three out of four patients displayed reduced expression of TIMP3 transcript in comparison with the corresponding normal region (Figure 1e ). Overall, this meta-analysis suggests that TIMP3 downregulation was found to be a general event in PTC carcinogenesis.
We investigated the expression of TIMP3 by reverse transcriptase-PCR (RT-PCR) in a panel of thyroid tumor cell lines (Supplementary Table S1 ) including PTC-derived (TPC1, NIM1, BCPAP and K1), follicular thyroid carcinoma-derived (WRO82-1) and anaplastic thyroid carcinoma-derived (FRO81-2, FB1, BHT101 and 8505C) cell lines, and the human HEK293T cell line as control. Except for TPC1, which carries the RET/PTC1 oncogene, and for BHT101, for which no genetic lesion is known, all the other thyroid tumor cell lines harbor the BRAFV600E mutation (Schweppe et al., 2008; Vizioli and Greco, unpublished results) . The experiment reported in Figure 2a showed that TIMP3 expression is undetectable in TPC1 and NIM1 cell lines. Treatment with the demethylating agent 5-Aza-2 0 -deoxy-cytidine (5-Aza-dC) restored the TIMP3 mRNA expression, indicating that aberrant promoter hypermethylation silences the TIMP3 gene in TPC1 and NIM1 cells (Figure 2b ).
Restoration of TIMP3 expression does not affect growth rate of NIM1 cell line We produced an in vitro model based on the restoration of the TIMP3 expression in NIM1, a PTC-derived cell line harboring the BRAFV600E mutation (our unpublished results), derived from a metastasis and tumorigenic in nude mice (Zeki et al., 1993) . We constructed the TIMP3-myc expression plasmid carrying the TIMP3 cDNA fused in frame with the myc epitope and producing a 27 kDa TIMP3-myc protein reacting with both anti-myc ( Figure 3a ) and anti-TIMP3 antibodies (data not shown), as assessed by western blot analysis of transiently transfected NIM1 cells. The TIMP3-myc expression construct was used to generate NIM1 clones expressing the exogenous TIMP3-myc protein, following transfection and selection in geneticin. Western blot analysis identified 11 out of 27 independent clones expressing variable levels of TIMP3-myc protein (data not shown). Three NIM1-TIMP3 clones, named NIM1-T11, NIM1-T14 and NIM1-T23, were further characterized. The exogenous TIMP3-myc protein was detectable in both the cell extracts and the conditioned media (CM), as shown in Figure 3b .
TIMP3 inhibits, among others, TACE/ADAM17, a convertase involved in the production of soluble TNF-a (Fata et al., 2001) . Thus, the cleavage of TNF-a represents a read-out of TIMP3 activity. The TNF-a present in CM of NIM1-TIMP3 clones was determined by flow cytometric analysis, as described in Materials and Methods; as control clones transfected with empty vector (NIM1-EV) were used. As shown in Figure 3c , the amount of soluble TNF-a in NIM1-TIMP3 clones was drastically reduced with respect to NIM1-EV clones, thus demonstrating the activity of TIMP3-myc TIMP3 and thyroid carcinogenesis MC Anania et al protein.
Further evidence was provided by the reduction in NIM1-TIMP3 clones CM of syndecan4 and ALCAM (activated leukocyte cell adhesion molecule), the two other proteins whose shedding is mediated by TACE/ ADAM17 (Fata et al., 2001; Rosso et al., 2007) , as reported later. We determined the effect of TIMP3 on NIM1 growth rate by different approaches. In cells exposed to conditioned medium containing or not TIMP3 protein (hereafter indicated as CM þ and CMÀ, derived from NIM1-T23 or untransfected NIM1 cells, respectively), no differences in growth rate were observed ( Figure 3d ). In keeping with these results, NIM1-TIMP3 clones and the control NIM1-EV clones showed the same cell cycle distribution by flow cytometric analysis, no evidence of apoptosis (Supplementary Information and Supplementary Figure S1 ) and a similar level of activation of the major signal transduction pathways (AKT, extracellular signal-regulated kinases (ERKs) and c-Jun N-terminal kinase (JNK); data not shown). Collectively, these data indicate that TIMP3 is not involved in the regulation of growth of NIM1 cells.
TIMP3 increases NIM1 cell adhesion
When NIM1 cells were plated at low density in CM þ or CMÀ, no differences in colonies number or dimension were observed at days 10 and 17 (data not shown), in keeping with the lack of effect of TIMP3 on growth rate described above. Instead, a difference was observed at day 24: NIM1 colonies grown in CM þ were more compact and dense than those in CMÀ, which underwent cell detachment (Figure 4a ), suggesting an effect of TIMP3 on cell adhesion. To further dissect this issue, we performed an adhesion assay in which NIM1 cells were pretreated with CM þ or CMÀ for 24 h, seeded in a 96-plate coated with type IV collagen, a component of extracellular matrix, in the presence of the same media, and the number of cells attached to substrate at 1 h after seeding was measured. As shown in Figure 4b , treatment with CM þ increases by 1.4-fold the adhesion of NIM1 cells. Similar results were obtained in the presence of recombinant TIMP3 protein, which caused a 1.8-fold increase in NIM1 cell adhesion (Figure 4c ), thus ruling out the possibility of ascribing the abovereported results to the presence in the CM þ of secreted factors other than TIMP3. The adhesion assay was also applied to NIM1-TIMP3 clones; all of them showed a two-to three-fold increase in adhesion with respect to NIM1-EV control clones ( Figure 4d ). Collectively, these data demonstrate the involvement of TIMP3 in the regulation of NIM1 cell adhesion.
TIMP3 reduces migration, invasion and anchorage-independent growth of NIM1 cells
To investigate the migratory capability of NIM1-TIMP3 clones, we first performed the wound healing assay. As shown in Figure 5a , the NIM1-TIMP3 clones showed reduced wound healing capability with respect to NIM1-EV clones. At 24 h, the scratch of control clones was completely healed, whereas that of NIM1-TIMP3 clones was repaired by 39 to 79%. Comparable results were obtained in the presence of recombinant TIMP3 protein, which reduced migration capability of NIM1 cells by B50% at 8 and 24 h after scratching (Figure 5b ). To corroborate our results, we investigated the effect of TIMP3 silencing on the migration capability of K1 cells, derived from a PTC, carrying the BRAFV600E mutation and expressing high amount of TIMP3 mRNA (Figure 2a ). K1 cells transiently transfected with TIMP3 small interfering RNA showed abrogation of TIMP3 expression (Figure 5c , left). Concomitantly, a 2.3-fold increase of migration capability, with respect to control, was observed, as assessed by wound healing assay (Figure 5c , right).
We next performed Boyden chamber assays in order to investigate both the migratory and invasive capabilities of NIM1-TIMP3 and NIM1-EV clones using their own CM as chemoattractant. In the migration assay, all the NIM1-TIMP3 clones showed a drastic reduction (78-87%) with respect to the control NIM1-EV clones (Figure 6a, top) . When the assay was performed in the presence of Matrigel, very similar results were obtained, with NIM1-TIMP3 clones showing invasion capability reduced by 86-95% with respect to NIM1-EV clones (Figure 6a, bottom) .
To rule out the possibility that the above-reported data could be ascribed to clone variability, we performed Boyden chamber assays in which NIM1 cells transiently transfected with TIMP3-myc or empty vector were exposed to their own or the other CM as chemoattractant. In this case, CM þ and CMÀ were derived from TIMP3-myc or empty vector transiently transfected cells, respectively. The results are reported in Figure 6b . NIM1-TIMP3-transfected cells exposed to CM þ showed reduction of migration (33%) in comparison with CMÀ. Similarly, the migration of EV-transfected NIM1 cells was reduced by 49% when CM þ was used as chemoattractant in comparison with CMÀ. The invasion assay showed similar results: the invasive capability of NIM1-TIMP3-transfected cells in the presence of CM þ was reduced by 47% in comparison with that in the presence of the CMÀ. Similarly, NIM1-EV cells showed a 51% reduction of invasion in the presence of CM þ with respect to CMÀ. As above reported for adhesion and wound healing assays, results consistent with those in the presence of CM þ were obtained by performing invasion assay in the presence of recombinant TIMP3 protein: here again, a consistent reduction (41%) of invasiveness of NIM1-EV cells was detected.
Tumor cells display the capability to grow in the absence of adhesion. To investigate whether this feature in NIM1 cells is affected by TIMP3, we performed soft agar assay. For these experiments, we used NIM1-TIMP3 clones and, as control, the NIM1-EV1 clone and untransfected NIM1 cells. After 3 weeks of incubation in soft agar NIM1-TIMP3 clones formed colonies with efficiency reduced (68-91%) with respect to control cells (Figure 6c, left) . Moreover, the soft agar clones formed by NIM1-TIMP3 cells were smaller than those of the control cells (Figure 6c , right).
Analysis of proteins mediating TIMP3 effects
To gain more insight into the regulation of cell adhesion, migration and invasion by TIMP3, we investigated the status of several proteins involved in these processes. As anticipated earlier, we investigated the status of syndecan4 and ALCAM, the two proteins involved in cell adhesion and regulated by shedding mediated by ADAM17/TACE, a TIMP3-sensitive metalloprotease (Fata et al., 2001; Rosso et al., 2007) . The soluble form of syndecan4 was less abundant in CM of NIM1-TIMP3 clones with respect to control, as demonstrated by immune dot blot (Figure 7a, top) . Similarly, the level of 96 kDa soluble form of ALCAM, detected by western blot, was reduced in NIM1-TIMP3 clones with respect to control (Figure 7a, bottom) . E-cadherin, an adhesion molecule whose deficiency in cancer cells promotes invasion (Margineanu et al., 2008) , was undetectable in naive NIM1 cells, in keeping with their metastatic origin, and its expression was not restored in TIMP3-expressing clones. As control, the expression of E-cadherin in human primary thyrocytes is shown (Figure 7b ). Vimentin is involved in invasion and its expression is upregulated in several tumors, including PTC (Vasko et al., 2007) . As shown in Figure 7c (top), the vimentin level in NIM1-TIMP3 clones was reduced with respect to NIM1-EV cells.
Cytokeratin 8/18 are regulators of integrin-dependent adhesion and migration (Bordeleau et al., 2010) ; their level increased in NIM1-TIMP3 clones with respect to control (Figure 7c, bottom) .
On the whole, these data indicate that TIMP3 regulates adhesion, invasion and migration of NIM1 cells by modulating the amount of syndecan4, ALCAM, vimentin and cytokeratin 8/18.
Effect of TIMP3 restoration in mouse tumor xenografts
To investigate the in vivo consequences of TIMP3 reexpression in NIM1 cells, NIM1-TIMP3 clones and NIM1 cells were injected into nude mice. Tumor growth was observed in 3/3 mice injected with NIM1 cells. In mice xenografted with NIM1-T11 cells, 3/3 takes were observed, but regression occurred in 1/3 animal. In mice injected with NIM1-T14 and NIM1-T23, tumor growth was observed in 2/3 mice. Collectively, tumors produced by NIM1-TIMP3 clones grew more slowly than NIM1 tumors (Table 1) .
As soon as tumors were visible through the skin of nude mice, TIMP3-expressing tumors appeared paler than NIM1-induced tumors. This difference was confirmed at excision; in addition, TIMP3-expressing tumors were less hemorrhagic compared with NIM1-induced tumors (data not shown). Cell cultures were established from explanted tumors. Western blot analysis confirmed the expression of TIMP3 protein in tumor-derived cells (Figure 8a ). In addition, functional analysis of xenograft-derived cells revealed that TIMP3-expressing cells maintain the reduction of wound healing, migration and invasion relative to NIM1 cells (Figures 8b-d) . Histopathologically, both NIM1 and NIM1-TIMP3 subcutaneous tumor xenografts appeared as welldemarcated expansile multinodular growths. Tumor tissue was composed of large polygonal anaplastic epithelial cells arranged in small densely cellular lobules and papillary projections often delimiting central cystic spaces. These tumor units were supported by variable amount of fibrovascular stroma and surrounded by a loose capsular reaction with sparse infiltration of inflammatory cells. Locally extensive necrohemorrhagic areas were consistently observed at the periphery of NIM1-induced tumors. Similar lesions were not observed in association with NIM1-TIMP3-induced tumors ( Figure 9 , hematoxylin and eosin). Taken together, these findings may explain why grossly detectable hemorrhages were recorded in tumor xenografts deriving from NIM1 but not from NIM1-TIMP3 cells.
To assess the extent of vascularization in tumor xenografts, we determined the microvessel density by immunohistochemistry with anti-mouse CD31 antibody (Figure 9, CD31) . The mean microvessel count in TIMP3-expressing tumors was reduced with respect to NIM1-induced tumors; for T23 tumors, the difference was statistically significant.
In several human tumors, including thyroid cancer and related animal models, it has been observed that tumor angiogenesis correlates with the extent of macrophage infiltration (Russell et al., 2003; Detoraki et al., 2009) . To investigate the presence of infiltrating macrophages in our in vivo tumor model, we evaluated their presence at tumor edges by immunohistochemistry with F4/80 antibodies. As shown in Figure 9 (F4/80), the number of macrophages was significantly reduced in tumors expressing TIMP3 with respect to those induced by naive NIM1 cells.
Discussion
By an integrated approach including analysis of gene expression data and functional studies, we have demonstrated that TIMP3 exerts a negative regulatory role in thyroid carcinogenesis. Analysis of gene expression data produced in our laboratory demonstrated consistent downregulation of TIMP3 in PTC with respect to normal thyroid, and also highlighted an association with the tall cell variant. Downregulation of TIMP3 in PTCs with respect to normal thyroid was also observed by in silico analysis of three different publicly available gene expression data sets. Collectively, the gene expression data support the notion that TIMP3 may exert an oncosuppressor role in PTC, as also proposed by previous studies. In fact, TIMP3 gene was found to be downregulated in primary thyrocytes infected with RET/PTC1 retroviral vector with respect to uninfected cells (Borrello et al., 2005) . Moreover, TIMP3 was identified within a group of tumor-suppressor genes (also including SLC5A8, DAPK and RARb2) hypermethylated in a consistent fraction (53%) of PTCs in association with tumor aggressiveness and BRAF mutation (Hu et al., 2006) . Promoter hypermethylation is also the mechanism silencing TIMP3 gene expression in two PTC-derived tumor cell lines (TPC1 and NIM1), as levels of TIMP3 mRNA rose upon treatment with the demethylating 5-Aza-dC agent.
To determine the contribution of TIMP3 to thyroid carcinogenesis, we restored its expression in NIM1, a PTC-derived cell line. This was achieved by exposure to TIMP3-containing CM and by transient or stable transfection of TIMP3-myc cDNA. No effects on growth control, induction of apoptosis and activation levels of major signal transduction pathways functioning in NIM1 cells were observed. Different effects of TIMP3 restoration on tumor cell growth have been reported. No effect on in vitro proliferation of murine neuroblastoma and melanoma cells was observed (Spurbeck et al., 2002) ; on the contrary, in human melanoma, neuroblastoma and malignant peripheral nerve sheath tumor, TIMP3 was reported to induce apoptosis (Ahonen et al., 2003; Mahller et al., 2008) . The lack of effect of TIMP3 on the growth rate of NIM1 cells might be related to their thyroid origin and/or to the advanced tumor stage they represent, being derived from a PTC metastasis. In this context, it is worth noting that multiple elements contribute to growth regulation of NIM1 cells. In addition to the BRAFV600E mutation, NIM1 cells carry homozygous deletion of the tumor-suppressor p16INK4 (Calabro et al., 1996) , produce multiple cytokines, including GM-CSF, IL-6 and IL-11, and their growth is regulated by IL-1 through an autocrine mechanism (Tohyama et al., 1992; Zeki et al., 1993) . Moreover, we have recently demonstrated that the growth of NIM1 cells is regulated by an autocrine transforming growth factor-a/epidermal growth factor receptor loop (Degl'Innocenti et al., 2010) and by the IGFBP7 pathway (Vizioli et al., 2010) .
Although not involved in growth control, TIMP3 modified some features of the transformed phenotype of NIM1 cells. Cells exposed to soluble TIMP3 or transfected with TIMP3-myc construct showed increased adhesion and reduced migratory and invasive capabilities. Analysis of some cell adhesion mediators in TIMP3-expressing clones showed reduction of syndecan4 and ALCAM shedding and vimentin protein level, and increase of the epithelial marker cytokeratin. All these features, consistent with the inhibitory effect of TIMP3 on matrix metalloproteinases and on ADAM17/ TACE, indicate a reduced degradation of the extracellular matrix, and suggest that the transformed phenotype of NIM1 cells can be modulated by TIMP3 restoration.
The most striking effect of TIMP3 restoration in NIM1 cells was observed in mouse tumor xenografts. When compared with NIM1-induced tumors, TIMP3-expressing tumors showed consistently reduced growth and appeared paler and less hemorrhagic. In this context, histopathological examination confirmed the presence of hemorrhagic areas in NIM1-induced tumors, but not in TIMP3-expressing tumors. In keeping with this, angiogenesis was reduced in TIMP3-expressing tumors, as assessed through the evaluation of microvessel density, and this was associated with reduction of tumor-infiltrating macrophages. The antiangiogenic effect of TIMP3 observed in tumor xenografts suggests a link between frequent increase of angiogenesis and TIMP3 downregulation detected in PTC (Akslen and LiVolsi, 2000; Hu et al., 2006) . It has been described that the antiangiogenic effect of TIMP3 is related to its inhibition of VEGFA binding to VEGFR-2, thus attenuating downstream signaling (Qi et al., 2003) , and that VEGFR inhibition is responsible for the antitumoral role of TIMP3 in several models (Ahonen et al., 2003; Mahller et al., 2008) . Based on the evidence that NIM1 cells produce VEGFA (Melillo et al., 2010) , the same mechanism could be responsible for the effects observed in our tumor xenograft model.
The reduction of infiltrating macrophages in TIMP3-expressing tumors is worth noting, as in thyroid epithelial tumors the extent of macrophage infiltration is associated with progression (Ryder et al., 2008) . It has been demonstrated that inhibition of VEGFA binding to VEGFR-2 reduces macrophage infiltration in orthotopic xenografts of pancreatic and breast tumors (Dineen et al., 2008; Roland et al., 2009) . Thus, it is tempting to speculate that in our tumor model the inhibitory effect of TIMP3 for VEGFA binding to VEGFR-2 may be responsible for reduction of both angiogenesis and macrophage infiltration, thus leading to restriction of in vivo tumor growth. Further studies are needed to dissect the mechanisms through which TIMP3 regulates angiogenesis and macrophage infiltration in PTC.
Although a role for tumor-suppressor genes in thyroid carcinogenesis has not been assessed yet, functional studies have allowed some genes downregulated in PTCs to be classified as tumor suppressors, based on their ability to modulate transformed properties of thyroid tumor cell lines (Ferrario et al., 2008; Latini et al., 2008; Pallante et al., 2008; Vizioli et al., 2010; Zuo et al., 2010) . With this study, we have demonstrated that TIMP3 exerts a negative regulatory role in thyroid tumor cells, thus corroborating its oncosuppressor role suggested by hypermetylation and gene expression studies. In addition to unveiling a novel mechanism involved in thyroid carcinogenesis, our data suggest that restoration of TIMP3 activity might be taken into account for the design of new therapeutic strategies for thyroid tumors.
Materials and methods

Microarray data sets and statistical analysis
The expression of TIMP3 was examined on microarray data sets containing normal thyroid and PTC tissues. The details are described in the Supplementary Data. Statistical analysis and graphs were generated using GraphPad Prism version 5.0 (GraphPad Prism Software, Inc., La Jolla, CA, USA). Comparison between two groups was performed, for unmatched samples by the nonparametric Mann-Whitney test, and for matched samples by Wilcoxon signed pairs test. When three or more groups were considered, analysis of variance followed by post tests was performed. Po0.05 was considered significant.
RNA extraction and RT-PCR
RNA extraction was performed using TRIZOL reagent (Invitrogen, Carlsbad, CA, USA). RNA (1 mg) was retrotranscribed using SuperscriptIII (Invitrogen). TIMP3 amplification by RT-PCR was performed as reported in the Supplementary Data.
Construction of TIMP3 expression vector
The TIMP3 cDNA was isolated by RT-PCR from a human placenta cDNA library using the following primers: 5 0 -CC GGAATTCGGCGGCAGCGGCAATGA-3 0 and 5 0 -CGCGG ATCCGGGGTCTGTGGCATTGATGATGCTT-3 0 , containing the EcoRI and the BamHI restriction sites (in bold), respectively. The 650 nucleotides PCR product was digested with EcoRI and BamHI endonucleases and inserted into the pcDNA3.1/mycHis(À)A vector carrying compatible ends. The resulting construct carries the TIMP3 cDNA in the sense orientation with respect to the cytomegalovirus promoter present in the vector and encodes the TIMP3-myc fusion protein.
Cell lines, treatments and transfection
Culture conditions of the different cell lines are described in the Supplementary Information. CM were obtained by incubating subconfluent cultures in serum-free medium for 24 h. The recombinant TIMP3 protein (R&D Systems, Minneapolis, MN, USA) was used at 50 nM. Treatment with 5 mM 5-Aza-dC (Sigma Aldrich, St Louis, MO, USA) was applied for 4 days. Treatment with 100 ng/ml phorbol 12-myristate 13-acetate (PMA) (Sigma Aldrich) was applied for 2 h. Transient and stable transfections of NIM1 cells were performed using Lipofectamine LTX (Invitrogen). Cells (4 Â 10 5 ) were seeded in 60 mm dishes and transfected with 2 mg of plasmid DNA and 5 ml of LTX the following day. After 48 h, the transfected cells were either harvested and processed, or subjected to G418 (Lifetechnologies, Invitrogen, Carlsbad, CA, USA) selection (400 mg/ml). G418-resistant colonies were isolated and propagated in G418-containing medium 2 weeks later.
TIMP3 silencing
Knockdown of TIMP3 protein in K1 cells was performed by transfection with ON-TARGET plus SMART pool for human TIMP3 or NON-TARGET small interfering RNA control (ThermoScientific, Dharmacon Inc., Chicago, IL, USA) using Lipofectamine RNAiMax (Invitrogen) following the manufacturer's instruction. At 48 h after small interfering RNA delivery, transfected cells were assayed by RT-PCR for TIMP3 expression and by wound healing assay.
Western and dot blot analysis Details of Western blot analysis are reported in the Supplementary Information.
For dot blot, CM were harvested, concentrated by centrifugation at 4000 r.p.m. using AgilentSpin Concentrators (Agilent Technologies Inc., Wilmington, DE, USA), and applied to a nitrocellulose membrane (Hybond-C Super, GE Healthcare) under vacuum in an immunodot apparatus (Millipore). The membrane was blocked for 1 h with 5% bovine serum albumin in Tris-buffered saline/0.05% Tween and incubated overnight at 4 1C with anti-syndecan4 5G9 antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
TNF-a detection TNF-a concentration in CM, produced as above described, was evaluated using the FlowCytomix Kit (Bender MedSystems, Vienna, Austria), according to the manufacturer's instructions.
Growth curves
Growth curves were determined as previously described (Vizioli et al., 2010) .
Colony-forming assay NIM1 cells were plated at low density (200 cells in 60 mm culture dish) and cultured in the presence of CM. Colonies were fixed with methanol and stained with Giemsa (SigmaAldrich).
Cell adhesion assay
After 24 h of incubation with appropriated CM, cells (3 Â 10 4 cells per well) were seeded in sextuple in 96-well plate pretreated with 30 mg/ml type IV collagen (BD Biosciences, Bedford, MA, USA). After 1 h of incubation, non-attached cells were removed by gently washing twice with 100 ml phosphate-buffered saline. Attached cells were fixed with 10% buffered formalin solution for 20 min at room temperature, followed by staining in 0.2% (w/v) crystal violet for 10 min. Stained cells were lysed in 1% sodium dodecyl sulfate and the intensity of stain was quantified by a spectrometer at the absorbance of 595 nm (TecanUltra Tecan Trading AG, Switzerland).
Wound healing assay Cells were seeded in 60 mm dishes. At confluence, a scratch was applied with a tip. Plates were washed with phosphatebuffered saline, refed with complete medium and returned to the incubator. Pictures were taken at 0, 8 and 24 h at Â 10 magnification using a digital camera system coupled with a microscope (LEICA, DMIRB, Leica Microsystems GmbH, Wetzlar, Germany).
Migration and invasion assay
In the migration assay, cells were seeded in the upper chamber (1.2 Â 10 5 cells per well) of 24-well Transwell plates equipped with polycarbonate filters (Costar; Corning Incorporated, NY, USA), in serum-free medium. CM media were added to the lower chamber as chemoattractant. After 5 h of incubation at 37 1C, filters were cleaned on the upper side with a cotton swab, fixed with 99% ethanol and stained with a 0.4% sulforhodamine B/1% acetic acid solution. Migrated cells were counted under an inverted microscope in six randomly chosen fields. The same procedure was used for invasion assay, except that cells were seeded at 2.4 Â 10 5 cells per well in Transwell chambers coated with 12.5 mg of Matrigel per well (BD Biosciences), and samples were processed after 24 h of incubation. All samples were performed in duplicate.
Soft agar assay Soft agar assay was performed as previously described (Vizioli et al., 2010) . Pictures were taken at Â 4 magnification using a digital camera system coupled with a microscope (LEICA, DMIRB).
In vivo studies Animal studies were reviewed and approved by the Ethics Committee for Animal Experimentation of the Fondazione IRCCS 'Istituto Nazionale dei Tumori' and are in accordance with the guidelines of the UK Coordinating Committee for Cancer Research (UK Coordinating Committee on Cancer Research, 1988) . Female CD-1 nu/nu mice (8 to 9 weeks old) (Charles River, Calco, Italy) were injected subcutaneously into the left flank with 2 Â 10 6 cells in 0.2 ml phosphate-buffered saline volume. Tumor growth was assessed by evaluating tumor latency, that is, days to reach 0.1 g, and by monitoring tumor weight (TW) twice a week. TW was estimated by the formula TW(g) ¼ d2 Â D/2 where d and D are the shortest and the longest diameters of the tumor, respectively, measured in cm.
Immunohistological studies
Representative portions of excised tumor xenografts were fixed in 10% neutral buffered formalin, routinely processed and embedded in paraffin blocks. Sections 4 mm thick, were stained with hematoxylin and eosin and evaluated under a light microscope to assess the pattern of tumor growth. To establish the extent of tumor angiogenesis, serial sections were immunostained with a primary rat monoclonal antibody against CD31 antigen (clone SZ31, DIA 310 M, Dianova, Hamburg, Germany) and positive endothelial outlines identified within the tumor stroma and/or capsule were counted in four randomly selected Â 200 microscopic fields. To establish the number of histiocytes associated with the tumor growth, additional serial sections were immunostained with a primary rat monoclonal antibody against F4/80 antigen (clone Cl: A3-1, MCA497G, AbD Serotec, Kidlington, UK) and positive cells were counted in five Â 400 microscopic fields randomly selected along the tumor edge. Both the immunostains were performed using a standard immunoperoxidase protocol (Vectastain Elite ABC kit, PK-6100; Vector Laboratories, Inc., Burlingame, CA, USA) followed by diaminobenzidine chromogen reaction (Peroxidase substrate kit, DAB, SK-4100; Vector Lab 
